Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Arcellx

    - PMLiVE

    Gilead agrees on affordable medicines plan with US government

    The company recently announced a $32bn investment in US R&D and manufacturing

    - PMLiVE

    Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

    This is the most common type of non-Hodgkin lymphoma worldwide

    - PMLiVE

    J&J receives positive NICE recommendation for multiple myeloma treatment

    The treatment is approved for use within the NHS in England and Wales

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    Johnson & Jonson secures FDA approval for multiple myeloma treatment

    Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results

    - PMLiVE

    GSK’s Blenrep approved by FDA for multiple myeloma

    Approval supported by positive results from phase 3 trial

    - PMLiVE

    BMS acquires Orbital Therapeutics in $1.5bn deal

    The deal includes several next-gen cell therapy candidates for autoimmune diseases

    - PMLiVE

    Sanofi’s multiple myeloma candidate granted FDA orphan drug designation

    More than 180,000 people worldwide are diagnosed with the disease every year

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    - PMLiVE

    GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

    More than 50,000 cases of the blood cancer are diagnosed in Europe each year

    - PMLiVE

    Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

    The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

    - PMLiVE

    AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

    ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links